Detalhe da pesquisa
1.
Day 100 Natural Killer Cell/CD14+HLA-DRDIM ratio and survival in lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation.
Clin Transplant
; 38(1): e15211, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38041479
2.
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.
Haematologica
; 108(11): 3025-3032, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37102592
3.
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Am J Hematol
; 98(3): 464-471, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36629030
4.
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Br J Haematol
; 195(2): 201-209, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34341990
5.
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Hematol Oncol
; 39(5): 658-663, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34453851
6.
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience.
Biol Blood Marrow Transplant
; 26(12): 2217-2222, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32818553
7.
Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation.
Am J Hematol
; 95(10): 1170-1179, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32618000
8.
Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma.
Am J Hematol
; 94(7): 786-793, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31006875
9.
Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.
Am J Hematol
; 94(3): 291-298, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30516868
10.
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
Biol Blood Marrow Transplant
; 24(6): 1187-1195, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29410180
11.
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.
Blood
; 127(16): 1960-6, 2016 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26837698
12.
End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET.
Haematologica
; 108(6): 1697-1701, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546451
13.
Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study.
Haematologica
; 108(8): 2249-2254, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36601982
14.
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
Br J Haematol
; 178(3): 427-433, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28466487
15.
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.
Blood
; 126(3): 328-35, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25921059
16.
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
Am J Hematol
; 92(5): 448-453, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28211162
17.
Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma.
Biol Blood Marrow Transplant
; 22(6): 1017-1023, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26826432
18.
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.
Am J Hematol
; 91(2): 179-84, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26492520
19.
A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.
Br J Haematol
; 170(5): 679-86, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25974212
20.
Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma.
Biol Blood Marrow Transplant
; 20(11): 1804-12, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25042737